Patents Assigned to GO THERAPEUTICS, INC.
-
Patent number: 11860165Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: GrantFiled: June 18, 2021Date of Patent: January 2, 2024Assignee: GO Therapeutics, Inc.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Publication number: 20230126689Abstract: The present disclosure relates to anti-glyco-CD44 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of CD44 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.Type: ApplicationFiled: March 5, 2021Publication date: April 27, 2023Applicant: GO Therapeutics, Inc.Inventors: Julia SCHNABEL, Edwin TAN, Hans H. WANDALL, Aaron GROEN
-
Publication number: 20220089772Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.Type: ApplicationFiled: September 29, 2021Publication date: March 24, 2022Applicant: GO Therapeutics, Inc.Inventor: Thayer WHITE
-
Publication number: 20220065862Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: ApplicationFiled: June 18, 2021Publication date: March 3, 2022Applicant: GO THERAPEUTICS, INC.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Patent number: 11161911Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.Type: GrantFiled: October 23, 2018Date of Patent: November 2, 2021Assignee: GO Therapeutics, Inc.Inventor: Thayer White
-
Publication number: 20210269552Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.Type: ApplicationFiled: June 28, 2019Publication date: September 2, 2021Applicant: GO Therapeutics, Inc.Inventors: Thayer White, Hans H. WANDALL
-
Patent number: 11067578Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: GrantFiled: October 16, 2018Date of Patent: July 20, 2021Assignee: GO Therapeutics, Inc.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Publication number: 20190119400Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.Type: ApplicationFiled: October 23, 2018Publication date: April 25, 2019Applicant: GO Therapeutics, Inc.Inventor: Thayer WHITE
-
Publication number: 20190101541Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: ApplicationFiled: October 16, 2018Publication date: April 4, 2019Applicant: GO THERAPEUTICS, INC.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Patent number: 10139414Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: GrantFiled: March 6, 2017Date of Patent: November 27, 2018Assignee: GO THERAPEUTICS, INC.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Patent number: 9588121Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilizing a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualization and treatment of specific cancer types.Type: GrantFiled: November 5, 2010Date of Patent: March 7, 2017Assignee: GO THERAPEUTICS, INC.Inventors: Hans H. Wandall, Johannes W. Pedersen, Eric P. Bennett, Henrik Clausen, Ulta Mandel